日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis

菲戈替尼在类风湿性关节炎治疗中显示出疗效,且不受吸烟状况的影响:3期临床试验的事后分析和基于索赔数据的分析

Curtis, Jeffrey R; Emery, Paul; Downie, Bryan; Zhong, Yan; Liu, Jinfeng; Han, Ling; Hawtin, Rachael E; Burmester, Gerd Rüdiger

Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis

基线中性粒细胞与淋巴细胞比值高的患者对菲尔戈替尼治疗类风湿性关节炎的反应更好

Taylor, Peter C; Downie, Bryan; Han, Ling; Hawtin, Rachael; Hertz, Angie; Moots, Robert J; Takeuchi, Tsutomu

Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy

用于狼疮治疗的 Toll 样受体 7/8 拮抗剂 MHV370 的临床前特性研究

Stuart Hawtin ,Cédric André ,Géraldine Collignon-Zipfel ,Simone Appenzeller ,Bettina Bannert ,Lea Baumgartner ,Damian Beck ,Claudia Betschart ,Thomas Boulay ,Hermine I Brunner ,Melanie Ceci ,Jonathan Deane ,Roland Feifel ,Enrico Ferrero ,Diego Kyburz ,Frederique Lafossas ,Pius Loetscher ,Christina Merz-Stoeckle ,Pierre Michellys ,Barbara Nuesslein-Hildesheim ,Friedrich Raulf ,James S Rush ,Giulia Ruzzante ,Thomas Stein ,Samantha Zaharevitz ,Grazyna Wieczorek ,Richard Siegel ,Peter Gergely ,Tamas Shisha ,Tobias Junt

First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults

MHV370(一种 Toll 样受体 7 和 8 的双重抑制剂)在健康成年人中的安全性、药代动力学和药效学的首次人体研究

Shisha, Tamas; Posch, Maximilian G; Lehmann, Jeanette; Feifel, Roland; Junt, Tobias; Hawtin, Stuart; Schuemann, Jens; Avrameas, Alexandre; Danekula, Rambabu; Misiolek, Patrycja; Siegel, Richard; Gergely, Peter

Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an In Vivo Efficacious TLR7/8 Antagonist

基于结构的TLR8结合筛选先导化合物结构优化,得到体内有效的TLR7/8拮抗剂

Betschart, Claudia; Faller, Michael; Zink, Florence; Hemmig, René; Blank, Jutta; Vangrevelinghe, Eric; Bourrel, Marjorie; Glatthar, Ralf; Behnke, Dirk; Barker, Kerstin; Heizmann, Andreas; Angst, Daniela; Nimsgern, Pierre; Jacquier, Sébastien; Junt, Tobias; Zipfel, Géraldine; Ruzzante, Giulia; Loetscher, Pius; Limonta, Sarah; Hawtin, Stuart; Andre, Cedric Bernard; Boulay, Thomas; Feifel, Roland; Knoepfel, Thomas

Envisaging an Effective Global Long-Term Agrobiodiversity Conservation System That Promotes and Facilitates Use

构想一个有效的全球长期农业生物多样性保护体系,以促进和便利其利用

Lusty, Charlotte; Sackville Hamilton, Ruaraidh; Guarino, Luigi; Richards, Chris; Jamora, Nelissa; Hawtin, Geoffrey

Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity

细胞因子诱导的JAK/STAT信号通路减弱与类风湿性关节炎及其疾病活动性相关。

Ptacek, Jason; Hawtin, Rachael E; Sun, Dongmei; Louie, Brent; Evensen, Erik; Mittleman, Barbara B; Cesano, Alessandra; Cavet, Guy; Bingham, Clifton O 3rd; Cofield, Stacey S; Curtis, Jeffrey R; Danila, Maria I; Raman, Chander; Furie, Richard A; Genovese, Mark C; Robinson, William H; Levesque, Marc C; Moreland, Larry W; Nigrovic, Peter A; Shadick, Nancy A; O'Dell, James R; Thiele, Geoffrey M; Clair, E William St; Striebich, Christopher C; Hale, Matthew B; Khalili, Houman; Batliwalla, Franak; Aranow, Cynthia; Mackay, Meggan; Diamond, Betty; Nolan, Garry P; Gregersen, Peter K; Bridges, S Louis Jr

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.

JAK1 抑制剂 Filgotinib 可调节类风湿性关节炎的疾病相关生物标志物:两项随机对照 2b 期试验的结果

Tarrant Jacqueline M, Galien René, Li Wanying, Goyal Lovely, Pan Yang, Hawtin Rachael, Zhang Wangshu, Van der Aa Annegret, Taylor Peter C

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients

通过单细胞网络分析确定转移性乳腺癌患者的基线 T 细胞功能障碍

Silvia C Formenti, Rachael E Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H McBride, Sandra Demaria

Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure

通过氟化调节 ADME 特性:提高口服暴露量的 MK2 抑制剂

Velcicky, Juraj; Schlapbach, Achim; Heng, Richard; Revesz, Laszlo; Pflieger, Daniel; Blum, Ernst; Hawtin, Stuart; Huppertz, Christine; Feifel, Roland; Hersperger, Rene